Item 2.02 Results of Operations and Financial Condition.

On February 27, 2020, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter and year ended December 31, 2019. A copy of the Press Release is furnished herewith as Exhibit 99.1.

On February 18, 2020, Nektar announced that it would hold a Webcast conference call on February 27, 2020 to review its financial results for the quarter and year ended December 31, 2019. This conference call is accessible through a link that is posted on the home page and Investors section of the Nektar website: http://ir.nektar.com.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.






Exhibit
  No.     Description

 99.1       Press release titled "Nektar Therapeutics Reports Fourth Quarter and
          Year-End 2019 Financial Results" issued by Nektar Therapeutics on
          February 27, 2020.




                                       1

© Edgar Online, source Glimpses